myo-Inositol, 1-(2,3-dihydroxypropyl hydrogen phosphate) | 966-66-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: myo-Inositol, 1-(2,3-dihydroxypropyl hydrogen phosphate)
• 英文别名: 2,3-dihydroxypropyl (2,3,4,5,6-pentahydroxycyclohexyl) hydrogen phosphate
• CAS: 966-66-5
• 化学式: C₉H₁₉O₁₁P
• 分子量: 334.21
• InChiKey: BMVUIWJCUQSHLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.6
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  197
• 氢给体数：
  8
• 氢受体数：
  11

文献信息

• Method and composition for cryopreservation of tissue
  申请人：Glonek, Thomas

  公开号：EP0354474A2

  公开（公告）日：1990-02-14

  Cryoprotectant agents and solutions are disclosed that are phosphomono and phosphodiester catabolites of phosphoglycerides. The cryoprotectants permit cold-preservation of cellular material minimizing damage caused by freezing and thawing. The cellular material cooled and/or frozen in accordance with the invention may be of animal or vegetable origin.

  已公开的低温保护剂和溶液是磷甘油酯的磷单酯和磷二酯分解物。这种低温保护剂可对细胞材料进行低温保存，最大限度地减少冷冻和解冻造成的损害。根据本发明冷却和/或冷冻的细胞材料可以是动物或植物来源。
• Urokinase-type plasminogen activator receptor
  申请人：Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning)

  公开号：EP1013285A2

  公开（公告）日：2000-06-28

  The use of substances capable of preventing the binding of a receptor binding form of u-PA to a u-PA receptor (u-PAR) in a mammal and thereby preventing u-PA from converting plasminogen into plasmin thereby preventing cell surface plasminogen activation which is believed to play an important role in tissue remodelling, particularly during cancer invasion for preparing a composition for preventing or counteracting localized proteolytic activity in a mammal, in particular a human.

  使用能够阻止 u-PA 受体结合形式与哺乳动物体内的 u-PA 受体（u-PAR）结合，从而阻止 u-PA 将纤溶酶原转化为纤溶酶，从而阻止细胞表面纤溶酶原活化的物质，这种活化被认为在组织重塑，特别是癌症侵袭过程中发挥重要作用，用于制备一种组合物，防止或抵消哺乳动物，特别是人类的局部蛋白水解活性。
• Use of antibodies against the urokinase receptor
  申请人：Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning)

  公开号：EP1281404A2

  公开（公告）日：2003-02-05

  The present invention discloses the use of a monoclonal or polyclonal antibody directed against urokinase plansminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. The antibodies react with free u-PAR or with complexes between u-PA and u-PAR and are able to inhibit the binding of pro-u-PA and active u-PA to u-PAR and thereby inhibit cell surface plasminogen activation. Thus, methods for preventing or counteracting proteolytic activity in a mammal is disclosed. Furthermore are screening methods for selecting substances suitable for inhibiting u-PA/u-PAR interactions disclosed. The substances identified by the screening method and the antibodies directed against u-PAR can be used for preventing or counteracting localized proteolytical activity in a mammal, such as for inhibiting the invasion and/or metastasis in a mammal.

  本发明公开了一种针对尿激酶计划氨原激活剂受体（u-PAR）或其子代、类似物或糖基化变体的单克隆或多克隆抗体的用途。抗体与游离的 u-PAR 或 u-PA 与 u-PAR 之间的复合物反应，能够抑制原 u-PA 和活性 u-PA 与 u-PAR 的结合，从而抑制细胞表面纤溶酶原的活化。因此，本研究公开了防止或抵消哺乳动物体内蛋白水解活性的方法。此外，还公开了用于选择适合抑制 u-PA/u-PAR 相互作用的物质的筛选方法。通过筛选方法确定的物质和针对 u-PAR 的抗体可用于防止或抵消哺乳动物体内的局部蛋白水解活性，如抑制哺乳动物的侵袭和/或转移。
• NOVEL PHOSPHOLIPID PROCESSING AGENT
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1918371A1

  公开（公告）日：2008-05-07

  Problems: It is an object of the present invention to provide a novel phospholipase B (PLB) having less hydrolytic activity on phosphatidylinositol (PI) among diacyl form of the phospholipid. Also, it is an object of the invention to provide a method of efficiently manufacturing PI and glyceryl phosphoryl choline (GPC) from a phospholipid mixture by using a substrate specificity of an enzyme. Means to Solve the Problems: Provided is a phospholipid processing agent containing an enzyme, which acts effectively on a phospholipid other than PI, such as phosphatidyl choline (lecithin), and having less PLB activity on PI.

  问题本发明的目的是提供一种新型磷脂酶 B (PLB)，它对二酰基形式磷脂中的磷脂酰肌醇 (PI) 具有较低的水解活性。此外，本发明的目的还在于提供一种利用酶的底物特异性从磷脂混合物中高效制造 PI 和甘油磷酸胆碱（GPC）的方法。 解决问题的方法：本发明提供了一种含有酶的磷脂加工剂，它能有效地作用于 PI 以外的磷脂，如磷脂酰胆碱（卵磷脂），并且对 PI 的 PLB 活性较低。
• Systems, methods, and biomarkers for determining the metabolic state of red blood cells and platelets
  申请人：Bordbar Aarash

  公开号：US10557861B2

  公开（公告）日：2020-02-11

  Disclosed herein are methods, biomarkers, systems, compositions and kits for determining the phase or metabolic state (e.g. First Phase, Second Phase, or Third Phase) of a red blood cell (RBC) sample or for determining the phase or metabolic state (e.g., First Phase or Second Phase) of a platelet (PLT) cell sample. The methods disclosed herein are related to the use of isolated RBC sample or isolated PLT sample and analytical tools for providing information that is relevant to the phase or metabolic state of the RBC sample or the PLT sample. The system disclosed herein utilizes isolated RBC sample or isolated PLT sample and at least one analytical tool or an output from the at least one analytical tool. The compositions and kits described herein utilize RBC samples or PLT samples, including compositions in a form that allows for analysis of the RBC sample or the PLT sample.

  本文公开了用于确定红细胞（RBC）样本的阶段或代谢状态（如第一阶段、第二阶段或第三阶段）或确定血小板（PLT）细胞样本的阶段或代谢状态（如第一阶段或第二阶段）的方法、生物标记物、系统、组合物和试剂盒。本文公开的方法涉及使用分离的 RBC 样品或分离的 PLT 样品和分析工具，以提供与 RBC 样品或 PLT 样品的阶段或代谢状态相关的信息。本文公开的系统利用分离的 RBC 样品或分离的 PLT 样品和至少一种分析工具或至少一种分析工具的输出。本文所述的组合物和试剂盒利用 RBC 样品或 PLT 样品，包括可对 RBC 样品或 PLT 样品进行分析的组合物。